Fluvastatin sodium hydrate

SIGMA/SML0038 - ≥98% (HPLC)

Synonym: (±)-(3R^*,5S^*,6E)-7-[3-(4-Fluorophenyl)-1-(1-methyethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate

CAS Number: 93957-55-2 (anhydrous)
Empirical Formula (Hill Notation): C₂₄H₂₅FNO₄ · Na · xH₂O
Molecular Weight: 433.45 (anhydrous basis)
MDL Number: MFCD20488050
Linear Formula: C₂₄H₂₅FNO₄ · Na · xH₂O
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-SML0038-10MG	10 mg	$117.00 1/EA	Add To Favorites
45-SML0038-50MG	50 mg	$450.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to tan
form	powder
InChI	1S/C24H26FNO4.Na.H2O/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);;1H2/q;+1;/p-1/b12-11+;;/t18-,19-;;/m1../s1
InChI key	KKEMYLLTGGQWCE-PMRANXHDSA-M
originator	Novartis
Quality Level	100
SMILES string	O.[Na+].CC(C)n1c(C=C[C@@H](O)C[C@@H](O)CC([O-])=O)c(-c2ccc(F)cc2)c3ccccc13
solubility	H₂O: ≥9 mg/mL
storage condition	desiccated
storage temp.	2-8°C

Application:	Fluvastatin sodium hydrate has been used: • to examine its effect on β -glucan-induced training on immunity • to investigate the effect of statins on the number of uncoupling protein 1 (UCP1)⁺ cells • to determine its effect on insulin degrading enzyme (IDE) secretion from astrocytes • to treat and study its effect on human umbilical vein endothelial cells (HUVECs) in vitro
Application:	Fluvastatin sodium hydrate has been used: • to test its anti-hepatitis C virus (HCV) activity • as a cholesterol inhibitor • to study its effects on β-glucan-induced monocyte immune training
Biochem/physiol Actions:	Fluvastatin has antifungal activity.
Biochem/physiol Actions:	Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.
Features and Benefits:	This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
Packaging:	10, 50 mg in glass bottle

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	2-8°C
UNSPSC	12352204

To Order From a Quote